SHINE to supply n.c.a. Lu-177 for the clinical development of ImaginAb investigational radiopharmaceuticals
SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.
A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.